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ABSTRACT Randomised controlled trials (RCTs) on the management of COPD exacerbations evaluate
heterogeneous outcomes, often omitting those that are clinically important and patient relevant. This limits their
usability and comparability. A core outcome set (COS) is a consensus-based minimum set of clinically
important outcomes that should be evaluated in all RCTs in specific areas of health care. We present the study
protocol of the COS-AECOPD ERS Task Force, aiming to develop a COS for COPD exacerbation management,
that could remedy these limitations.
For the development of this COS we follow standard methodology recommended by the COMET initiative.
A comprehensive list of outcomes is assembled through a methodological systematic review of the outcomes
reported in relevant RCTs. Qualitative research with patients with COPD will also be conducted, aiming to
identify additional outcomes that may be important to patients, but are not currently addressed in clinical
research studies. Prioritisation of the core outcomes will be facilitated through an extensive, multi-stakeholder
Delphi survey with a global reach. Selection will be finalised in an international, multi-stakeholder meeting. For
every core outcome, we will recommend a specific measurement instrument and standardised time points for
evaluation. Selection of instruments will be based on evidence-informed consensus.
Our work will improve the quality, usability and comparability of future RCTs on the management of COPD
exacerbations and, ultimately, the care of patients with COPD. Multi-stakeholder engagement and societal
support by the European Respiratory Society will raise awareness and promote implementation of the COS.
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Introduction
COPD, the third leading cause of death globally, has a growing prevalence and currently affects over 174
million people [1–3]. Acute exacerbations punctuate the natural history of COPD, determining disease
morbidity, mortality and progression [3–5]. Every year, up to 40% of patients diagnosed with COPD have
at least one moderate or severe exacerbation, while 9–16% experience more [6, 7]. As a result,
exacerbations are responsible for a significant proportion of all hospital admissions (one in eight in the
United Kingdom), while the 90-day mortality rate of an admission for an exacerbation exceeds 15%
[8–10]. Exacerbations are also associated with a substantial socioeconomic burden [3, 10].
While our understanding of the pathogenesis and underlying mechanisms of exacerbations is growing rapidly
[5, 11, 12], their management remains only partly effective and almost unchanged for decades [3, 8, 10].
Standard treatment still consists of three main components; bronchodilators, antibiotics and corticosteroids.
Therefore, novel treatments are to be expected, and an increasing number of clinical research studies will be
conducted in the coming years. These will include randomised controlled trials (RCTs) that can provide
conclusive evidence of the safety and effectiveness of an intervention, by minimising potential biases [13, 14].
Clinical trials seek to evaluate the safety, efficacy and/or clinical effectiveness of interventions by comparing
their effects on outcomes. Only a limited number of outcomes can be evaluated in each trial. Researchers
often select outcomes that are easier to measure, require fewer resources, are more likely to favour one
intervention over the other(s), or address specific hypotheses, which may be of limited importance to patients,
clinicians or the regulatory authorities [15]. Consequently, crucial data on potential beneficial or harmful
effects of interventions are often missed. This hampers the interpretability and potential value of RCTs, whose
main aim is to inform clinical guidelines and practice. Moreover, the use of different instruments to evaluate
the same outcome is likely to limit comparability.
Particularly in trials evaluating the management of COPD exacerbations, the definition of outcomes is still
vague and heterogeneous, while consistent use of relevant, comparable, patient important outcomes is
lacking. In a recent methodological systematic review [16, 17], we found significant heterogeneity in the
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outcomes assessed and reported by trials on the management of COPD exacerbations (table 1). Only 63%
of all RCTs conducted during the last decade assessed the proportion of patients whose exacerbations were
successfully treated or experience treatment failure, while less than 35% evaluated duration of the
exacerbation as an outcome (either the duration of a hospital admission or symptoms). Finally, there was
significant heterogeneity in the definition of outcomes and in the instruments used to evaluate them. This
lack of standardisation complicates interpreting, comparing, contrasting and synthesising the results of
RCTs. Thus, several recent meta-analyses on the management of COPD exacerbations have reported
limited certainty in the available evidence [18–20].
We report the study protocol of the COS-AECOPD study, which will be conducted to address these
limitations. We aim to develop a core outcome set (COS) to be used for RCTs evaluating the management
of COPD exacerbations. The aim of a COS is to develop global, multi-stakeholder consensus on a
minimum number of outcomes that future, relevant RCTs should measure and report on. It has been
demonstrated that when COS are implemented, they homogenise the design of RCTs, increase their
usability and comparability [21, 22]. Additionally, a COS for COPD exacerbations will improve the
possibilities for meaningful and statistically sound meta-analyses, helping to inform future clinical practice
guidelines.
This project is supported by the European Respiratory Society (ERS Task Force 2019–12) and the
European Lung Foundation (ELF). It is also supported by the DECODE-NET (DisEntangling Chronic
Obstructive pulmonary Disease Exacerbations clinical trials NETwork), an emerging clinical trials network
involving over 30 centres in Africa, Asia, Australia, Europe and America [23]. The DECODE-NET intends
to use the resulting COS in planned and future trials.
Methods
The Core Outcome Measures in Effectiveness Trials (COMET), an initiative aiming to bring together
people interested in the development and application of COS, has developed explicit methodology for the
development of COS. For the development and reporting of this COS, we follow explicit methodology
suggested by the COMET initiative (the COMET handbook), Core Outcome Set, STAndards for
Development (COS-STAD), Core Outcome Set, STAndards for Reporting (COS-STAR) and Core Outcome
Set, STAndardised Protocol Items (COS-STAP) documents (table 2) [24–27], which has already been
implemented successfully in several high-quality COS projects [28–30]. COMET recommends the
development of a comprehensive list of relevant outcomes followed by a prioritisation process, aimed to
select the most important (core) outcomes. The long list of outcomes is formed by a methodological
systematic review evaluating outcomes measured and reported in relevant RCTs. We have recently
completed the systematic review [17]; results are summarised in table 1. It is recommended that the list of
outcomes should also be informed by qualitative research aiming to elicit factors that are considered
TABLE 1 Frequency that different outcome measures were reported in 123 RCTs and 38 SRs
conducted during the past decade
Outcomes Frequency of reporting
RCTs SRs
Patient important outcomes
Mortality 101 (82%) 29 (76%)
Treatment success or failure 77 (63%) 29 (76%)
Adverse effects 73 (59%) 26 (68%)
Health status, symptoms & quality of life 73 (59%) 17 (45%)
Duration of exacerbations 42 (34%) 20 (53%)
Re-exacerbation, re-hospitalisation 33 (27%) 16 (42%)
Exercise capacity 14 (11%) 1 (3%)
Anxiety and depression 6 (5%) 1 (3%)
Surrogate, physiological and laboratory outcomes
Lung function 58 (47%) 18 (47%)
Arterial blood gases and oxygen saturation 40 (33%) 5 (13%)
Microbiological response 16 (13%) 7 (18%)
Biomarkers 32 (26%) 2 (5%)
Medication use 18 (15%) 3 (8%)
Data are presented as n (%). RCT: randomised control trial; SR: systematic review. Reproduced from [17].
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relevant and important to patients and their caregivers, that may not be evaluated in clinical research
studies. Prioritisation of the core outcomes is facilitated by a Delphi survey involving multiple
stakeholders, with a global reach and a consensus meeting with similar characteristics.
Study oversight
This study will be conducted by the COS-AECOPD ERS Task Force. A steering committee was formed
consisting of Alexander G. Mathioudakis, Jens-Ulrik Jensen, Jørgen Vestbo (clinical researchers with
expertise in trials focusing on COPD exacerbations), Carol Liddle (patient representative) and Paula
Williamson (COMET chair). The steering committee is responsible for the management and coordination
of the study. The steering committee will meet every 3 months (face to face or via teleconference), to
review the study progress, ensure the study complies with good clinical practice principles, relevant
regulations and adheres to the study protocol.
Qualitative research
We will conduct a focus group discussion, followed by semi-structured interviews, aiming to identify
outcomes that patients with COPD consider important. We will involve geographically spread participants
with different disease severity, age, cultural and socioeconomic backgrounds. More specifically, participants
will include male and female adults suffering from COPD, who have a history of a hospitalised exacerbations
or frequent moderate exacerbations (treated in the community), or exacerbations with concomitant
hypercapnic respiratory failure requiring noninvasive ventilation, during the preceding year. Some
participants will be approached while recovering from an exacerbation, and others during stable disease state.
Members of our team will recruit and interview patients in several countries with different socioeconomic
characteristics, across the globe (we plan to recruit patients from Africa, Americas, Asia, Australia and
Europe). Each participant will only be able to attend either one interview or the focus group meeting.
A focus group and semi-structured interviews using open-ended questions will be used to elicit participants’
expectations and concerns regarding COPD exacerbations and their views on the outcomes of exacerbations.
These questions were developed by academic and lay members (patients diagnosed with COPD) of our
research team, with input from a qualitative researcher ( JY), the COMET initiative chair (PW) and the
COMET qualitative research team. They are summarised in table 3. Some of the participants will also
TABLE 2 Compliance of the COS-AECOPD with the COS-STAD standards for COS development
Domain Standard COS-AECOPD
Scope Setting Clinical research, focusing on RCTs
Condition Treatment of acute exacerbations of COPD
Population Adults with COPD exacerbations of any severity
Interventions Any intervention
Stakeholder
involvement
Users Clinical researchers, trialists, guideline
developers, policy makers, regulators,
research funders, and the pharmaceutical
industry (with global representation)
Healthcare professionals Doctors, nurses, physiotherapists with
expertise in COPD (global representation)
Patients Patients with COPD and their carers (with
global representation)
Consensus
process
Initial list of outcomes to be
informed by patients’ and health
professionals’ views
Patients’ and healthcare professionals’ views
will be identified through methodological
systematic reviews and an extensive Delphi
study. Patients’ views will also be captured
through qualitative studies
A priori scoring process and
consensus definition
See Methods: Delphi survey
A priori criteria for including,
dropping or adding outcomes.
See Methods: Delphi survey
Avoid ambiguity of language used in
the list of outcomes
The phrasing of the outcomes will be reviewed
by the COS panel and the patients
participating in the COS focus groups
COS: core outcome set; COS-STAD: Core Outcome Set, STAndards for Development; RCT: randomised
control trial.
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contribute to the development of plain language descriptions of the identified outcomes. Think-aloud
techniques will be used to evaluate how they interpret the outcomes [31]. Qualitative studies will be
conducted in the language spoken in each participating country. All investigators who will contribute to the
interviews will receive relevant material and/or a short introductory training presentation, to strengthen
relevant skills and ensure consistency across the different study sites.
The focus group and all interviews will be audio recorded and anonymised. All outcomes described
directly or indirectly by participants will be extracted verbatim, grouped and translated in the English
language. The frequency that every outcome is volunteered by participants will be presented as a relative
measure of importance of the outcome. In addition, we will undertake thematic analysis with a framework
approach to data organisation [32], aiming to identify participants’ hopes and concerns regarding COPD
exacerbations and their treatment. We will explore differences in the responses of participants from
different geographic and socioeconomic backgrounds.
Delphi survey
A Delphi survey is a widely used method to develop consensus. Participants are asked to complete several
rounds of a questionnaire. In each round, participants are asked to review and consider adjusting their
responses, considering the aggregated responses of all participants during the preceding round [33]. An
international, multi-stakeholder Delphi survey will be conducted, to facilitate prioritisation of the core
outcomes, among those identified through the methodological systematic reviews and qualitative research.
We will invite representatives of four stakeholder groups to participate in the survey:
a) Patients diagnosed with COPD, who have experienced exacerbations, caregivers of such patients, or
representatives of such patients (e.g. patient organisations)
b) Health professionals caring for patients (e.g. doctors, nurses, physiotherapists)
c) Clinician researchers (health professionals who care for patients but are also involved in designing
research studies)
d) Other stakeholders, including regulators, policy makers, funders, guideline developers or those working
in health technology assessment organisations.
Participants will be informed about the rationale and importance of COS development and that they will
be required to respond to two Delphi rounds. We will use DelphiManager, a secure software developed by
the COMET initiative. The survey will be available in English and at least three other languages, which will
be selected with the aim of maximising the reach of the survey and based on the available resources.
Two-way translations will be prepared by members of our research team, in collaboration with the ELF,
and input from lay members of their COPD Patient Advisory Group.
We will use a modified Delphi approach proposed by the COMET initiative, involving two Delphi
rounds [34]. In the first Delphi round, all unique outcomes identified through systematic reviews and
qualitative research will be listed in scientific and plain language, and we will ask participants to rate the
importance of every outcome. We will also encourage participants to suggest additional outcomes they
TABLE 3 Pre-specified questions that will be used to facilitate the qualitative research
(semi-structured interviews) and the focus group
Pre-selected open-ended questions
Can you tell us about your experience of having an exacerbation (flare-up) of your COPD?
When you have a flare-up of your COPD, how does this impact your life?#
What treatments were you offered for your recent exacerbations? How do medicines for your flare-ups
make you feel? (Ask specifically for NIV)#
To what extent the effects of treatments you had for exacerbations matched your expectations?
What specifically have you hoped from the treatments for your COPD exacerbations?#
What concerns do you have about your future exacerbations (flare-ups)?
What are the most concerning effects of exacerbations in your life?
If a new treatment became available for COPD flare-ups, what specific effects would you like it to have on
you?#
Provide plain language description of the outcomes. Make sure the participants understand what an
outcome is: Which outcomes do you think are important to be evaluated?
Were there any outcomes that you considered important previously that were not mentioned during this
interview?
NIV: noninvasive ventilation. #: Ask specifically about physical/mental/social wellbeing.
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consider relevant. Any genuinely new outcomes (not overlapping with previously identified outcomes)
suggested by the respondents will be included in the subsequent Delphi round. In the next round, graphical
displays of the scores submitted from each stakeholder group during the first round will be presented to the
participants, who will be asked to rate the importance of the outcomes for a second time (figure 1). While
the aim of this survey will be to reach consensus, participants will not be under any pressure to change their
ratings if they do not want to.
In both rounds, participants will be asked to rate the importance of each outcome for clinical decision
making on a scale from 1 to 9, following guidance by GRADE ( Grading of Recommendations, Assessment,
Development and Evaluation). Scores between 1–3 signify an outcome of limited importance, 4–6 signify an
important but not critical outcome and 7–9 signify a critical outcome [35, 36]. Answers will be sought by all
stakeholder groups and responses by each group will be analysed separately, in each Delphi round.
Consensus will be defined after the second Delphi round, using the following methodology: outcomes rated
between 7–9 (critical) by ⩾70% and between 1–3 (of limited importance) by ⩽15% of all participants in
each stakeholder group, will be selected for inclusion in the COS. In parallel, outcomes that are rated
between 7–9 (critical) by ⩽50% of all participants in each stakeholder group will be excluded from the COS.
We have conducted extensive preparatory work to achieve a global reach of the survey. Invitations will be
sent to:
a) Members of the ERS with a documented interest in airway diseases.
b) Patients with COPD and their caregivers through the ELF’s network of local and national patient
organisations representing patients across the world. Also, patients diagnosed with COPD who have
subscribed to the UK’s National Institute for Health Research (NIHR) Research for the Future Initiative
and other similar organisations facilitating patients’ recruitment.
c) Clinical researchers, policy makers, guideline developers, regulators, research funders and industry
representatives from all continents who have published on COPD exacerbations during the last decade
and their emails were identified through extensive literature searches (>5000 unique emails).
For all these stakeholders, we have developed invitations that are compliant with the General Data
Protection Regulation and e-Privacy regulations.
Outcome measure instruments and timing
Outcome measure instruments refer to the specific methodology used to evaluate the impact of an
intervention on an outcome. More specifically, while outcomes answer the question “What to measure?”,
instruments refer to the question “How to measure it?”. For example, St George’s Respiratory
Questionnaire or the Clinical COPD Questionnaire are both instruments that assess the outcome health
status in COPD [17]. Often, different instruments are used for evaluating the same outcome, limiting the
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FIGURE 1 Delphi round 2. Respondents will be provided with the score distributions from the first Delphi round, stratified by stakeholder category.
Their previous scoring will also be highlighted. (In this example, the respondent’s score for this outcome was 8.) Respondents will be asked to
reconsider their scoring, based on the available data. They will be under no pressure to change their scores.
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comparability of the RCT results. For this reason, we will recommend a specific instrument for each of the
selected core outcomes.
The COnsensus-based Standards for the selection of health status Measurement Instruments (COSMIN)
recommends a thorough methodology for in-depth evaluation and selection of outcome instruments [37].
However, such extensive methodological studies are beyond the scope and resources of the COS-AECOPD
study. For this reason, we will follow a more pragmatic approach. For every candidate core outcome, we
will identify the instruments that were used in the studies included in our methodological systematic
review and we will note how frequently each instrument was used [17]. For outcomes that are often
evaluated by the same instrument (in >40% of the trials), we will strongly consider recommending this
instrument, unless important methodological issues are raised by any of the task force panel members. In
any other case, we will undertake focused literature searches of Medline/PubMed and the COSMIN
database, to identify studies evaluating the quality of every instrument. Our task force panel will review
available evidence and will provisionally prioritise the use of a single instrument after considering: 1) the
frequency each instrument has been used in RCTs; 2) the time and resources required to assess each
instrument; and 3) available data on their measurement properties as described by COSMIN
recommendations (validity, reliability, responsiveness and interpretability).
Timing of outcomes evaluation is also crucial as COPD exacerbations are acute, dynamic events.
Minimum timepoints for follow-up evaluation will be provisionally selected based on consensus among
the panel members and in consultation with ELF’s COPD Patient Advisory Group. To reach an informed
consensus, the task force members will review the timings of outcome evaluation in previous trials and the
impact of timing on the results.
Selection of the instruments and follow-up timepoints will be presented during the consensus meeting,
feedback will be invited by all participants and the recommendations will be finalised based on consensus
within the consensus group
Consensus meeting
A consensus meeting will take place during the ERS International Congress. Members of all previously
described stakeholder groups will be invited, including at least five patient representatives. Geographic and
socioeconomic diversity will be considered in the selection of participants.
During this meeting, results of the Delphi survey will be presented objectively, starting from all outcomes
that reached consensus for inclusion, or exclusion. Then, all outcomes will be discussed. All stakeholder
groups will be given the opportunity to comment and vote on the selection of the final, core outcomes. Our
aim will be to select a small number of the most important outcomes, to ensure practicality of use of this
COS. Relevant arguments for or against the inclusion of an outcome and the vote counts will be noted.
Next, results of the outcome instruments’ evaluation will be discussed. The group will finalise the selection
of a single instrument for every outcome and will decide on the recommended follow-up time points.
Reasoning for all decisions will be described narratively in the final study report.
Sample size
We did not conduct formal power calculations for this study, as there are no strict recommendations on
the number of participants in a qualitative study or Delphi survey. In the first stage (qualitative research),
we will interview at least 70 patients, and until we are confident that saturation has been achieved and
potential socioeconomic and geographic differences have been captured.
For the Delphi survey, we have developed a thorough strategy for recruiting members of each stakeholder
category and we aim to engage as many participants as possible, to develop global, multi-stakeholder
consensus, while also raising awareness about the issue and our COS. We anticipate a study population at
the range of hundreds.
Protocol registration
The study protocol of the COS-AECOPD ERS Task Force has been registered prospectively with the
COMET database (COMET ID: 1325).
Discussion
Comparability (and occasionally interpretability) of RCTs on COPD exacerbation management is
particularly problematic [17]. The COS-AECOPD ERS Task Force aims to remedy these limitations by
developing a COS for the management of COPD exacerbations, that will promote standardisation of the
outcomes and their measurement instruments reported in future RCTs.
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COMET suggests that a qualitative systematic synthesis could occasionally replace patient interviews. Our
qualitative review (unpublished data), yielded data from one previous systematic review and three primary
studies. Fatigue and psychological wellbeing emerged as outcomes of importance to patients that are rarely
tested in RCTs and systematic reviews and were included in the longlist of outcomes. However, confidence
on the findings, evaluated using CERQual methodology [38], was low, because of concerns regarding the
adequacy and relevance of the available data. Adequate understanding of patients’ needs and priorities is
crucial for the development of high-quality COS. Characteristically, qualitative studies conducted by the
OMERACT (Outcome Measures in Rheumatology) almost two decades ago identified fatigue as a crucial
outcome of rheumatoid arthritis [39]. Fatigue, which was previously not evaluated in RCTs, is currently
one of the most frequently reported and informative outcomes in that field. For these reasons, we decided
to conduct additional, original qualitative research to inform the COS-AECOPD.
For outcomes prioritisation, we decided to use the modified Delphi approach proposed by COMET.
Instead of asking the respondents to identify potential outcomes, we will feed the survey with outcomes
identified through intensive methodological and qualitative research and this will ensure that the longlist
of outcomes is more complete. Respondents will also be encouraged to suggest additional relevant
outcomes. Moreover, we will limit the number of Delphi rounds to two, to limit attrition. While two
rounds may not be adequate to reach consensus for many of the outcomes, the results will be fed to a
multi-stakeholder consensus group meeting for finalisation. This approach has been successfully utilised in
previous high-quality COS [28–30].
A potential limitation of this study is our pragmatic approach towards the selection of outcome
instruments and the follow-up timing, which will not fully adhere to the COSMIN recommendations. This
is very unlikely to affect the selection of instruments for simple, objective outcomes (such as mortality). It
might affect the selection of measures of composite or patient reported outcomes. However, selection of
instruments will be informed by: 1) focused literature searches of studies evaluating the measurement
properties of the instruments; 2) current standard research practice, as our aim is to enhance homogeneity
across different RCTs; and 3) the experience of several principal investigators and methodologists involved
in COPD exacerbations trials, who are involved in this task force. Moreover, while researchers will strongly
be encouraged to use the core outcomes in all future RCTs, they will also be encouraged to measure other
outcomes, that may be relevant to their interventions, RCTs or interests but may also include
methodological evaluation of alternative instruments.
High resource requirements for the evaluation of certain outcomes included in COS may limit their
implementation, especially in pilot or early phase studies. However, the outcomes identified through our
systematic reviews are simple and inexpensive to measure and can be captured after a relatively short
follow-up period [17]. In addition, costs and resource requirements will be considered by the panel when
selecting the outcome instruments. Finally, it would not be expected that early phase studies would include
the COS necessarily, however it may be important that they include some of the core outcomes, to gather
data that would help power the later-phase studies.
The outcomes suggested by different regulatory bodies may not be included in the COS-AECOPD. In this
case, investigators would be advised to evaluate both the outcomes required by the regulatory authorities
and the additional outcomes that will be proposed by this COS, which will be informed by a global,
multi-stakeholder agreement. It is anticipated that regulatory authorities are likely to start endorsing
high-quality COS in the near future. For example, the US Food and Drug Administration is currently
developing three COS in a pilot project (for other diseases) [40].
A major strength of the COS-AECOPD study is the strong design, which is based on a thorough
methodological systematic review and extensive qualitative research to develop a longlist of clinically
relevant outcomes and an extensive Delphi survey, aiming to develop consensus. Moreover, the global
reach and involvement of all relevant stakeholders, following an exhaustive strategy to recruit and engage
them, will facilitate the development of international consensus, improve awareness of the methodological
issues and enhance the COS implementation in future research studies. Societal support by the ERS will
also promote awareness and implementation.
The need for high-quality research on COPD exacerbations is prioritised by the ERS. Apart from this Task
Force, the Society is also supporting the CICERO (Collaboration In COPD ExaceRbatiOns) ERS Clinical
Research Collaboration, aiming to set up a pan-European, prospective observational cohort study of
patients hospitalised with COPD exacerbations, to evaluate their clinical and mechanistic characteristics [41].
As part of this project the CICERO team is developing relevant methodology, including a comprehensive
data collection plan for such studies. The two projects are developed in a collaborative fashion, where
pertinent interim data of each project will be shared and used to inform the following steps of each
project.
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Overall, it is our strong belief that the development of a COS for the management of COPD exacerbations
will improve the quality, comparability and usability of future RCTs and will consequently have a positive
impact on the management of COPD exacerbations, clinical practice guidelines and the care of patients
with COPD.
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